Clinical trial · Interventional
Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma
Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas
NCT02784015CI-TRIAL-00034932unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the treatment outcome of unresectable soft tissue sarcoma using response based treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unresectable Localized Soft Tissue Sarcoma | Soft Tissue Sarcoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Ifosfamide | Drug | Ifosfamide | ALIAS |
| Melphalan | Drug | Melphalan | ALIAS |
| Radiotherapy | Radiation | — | UNRESOLVED |
| Thiotepa |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Unresectable localized soft tissue sarcoma
- description
- 1. Six cycles of chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen. 2. Surgery, if possible 3. Concurrent chemoradiotherapy according to the treatment response (necrosis rate, tumor volume reduction, and residual FDG uptake in PET scan) 4. Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation, if there are still residual tumors after 9 cycle of chemotherapy, surgery, and radiotherapy. * 1st HDCT: carboplatin, thiotepa, etoposide * 2nd HDCT: cyclophosphamide, melphalan
- interventionNames
- Drug: Cisplatin
- Drug: Etoposide
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Ifosfamide
- Drug: Carboplatin
- Radiation: Radiotherapy
- Drug: Thiotepa
- Drug: Melphalan
Primary outcomes (1)
- measure
- Rate of event free survival
- timeFrame
- Up to 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with unresectable localized high grade soft tissue sarcoma Exclusion Criteria: * Patients with organ dysfunction (ejection fraction, liver function test, creatinine \> CTCAE grade 2)
References
Publications (0)
Data not yet available
No reference posted for this study.